P2X₂ receptors supply extracellular choline as a substrate for acetylcholine synthesis

Takuma Maruyama, Asuka Mano, Toshiyuki Ishii, Yoshihiko Kakinuma and Makoto Kaneda
Department of Physiology, Nippon Medical School, Tokyo, Japan

Keywords
acetylcholine; choline; choline transporter; cholinergic neuron; HEK293T cell; P2X₂ receptor

Correspondence
T. Ishii, Department of Physiology, Nippon Medical School, Sendagi 1-1-5, Bunkyo-ku, Tokyo 160-8602, Japan
Fax: +81-3-5685-3055
Tel: +81-3-3822-2131 ext.5241
E-mail: tishii@nms.ac.jp

(Received 17 September 2021, revised 3 November 2021, accepted 16 November 2021)
doi:10.1002/2211-5463.13332
Edited by Koji Yamanaka

Acetylcholine (ACh), an excitatory neurotransmitter, is biosynthesized from choline in cholinergic neurons [1–4] is a major excitatory neurotransmitter that plays an important role in both the central and peripheral nervous systems [5–10]. Choline uptake by cholinergic neurons is mediated by three types of choline transporters [11,12], the distribution of which differs. The high-affinity choline transporter (CHT1) is exclusive to the axon terminals of cholinergic neurons [11,13–16], while the intermediate-affinity transporter, choline transporter-like protein 1 (CTL1), or members of low-affinity choline transporters, polyspecific organic cation transporters (OCT1–3) and CTL2, are ubiquitous throughout the cell surface of multiple tissues [11,12]. The functions of these transporters also differ. A previous study demonstrated that ACh concentrations were reduced in the cerebral cortex, hippocampus, and striatum of CHT1 +/− mice [17]. The application of hemicholinium-3 (HC-3), an inhibitor of CHT1 and CTL1, suppressed the release of ACh in the rat striatum [18]. Furthermore, reductions in the synthesis of ACh following the application of HC-3 were reported in the rat retina [19]. Choline taken up through CHT1 is used in the synthesis of ACh (Fig. 3A) [11,20,21], whereas that taken up by intermediate- or low-affinity choline transporters is used to synthesize phospholipids [11,12,22]. Therefore, the activity of cholinergic neurons has been assessed based on the activity of CHT1 [23].

Abbreviations
Ach, acetylcholine; ChAT, choline acetyltransferase; CHT1, high-affinity choline transporter; CTL, choline transporter-like protein; HEK293 cells, human embryonic kidney 293-derived cells; HEK293T cells, human embryonic kidney 293-derived cells that express the simian virus 40 T antigen; PB, phosphate buffer.
In the retina, ACh is released from cholinergic amacrine cells [19,24]. We recently demonstrated that P2X2 receptors, a subtype of P2X purinoceptors that form nonselective cation channels [25,26], function as an alternative pathway for choline entry in the cholinergic amacrine cells of the mouse retina [27]. However, it currently remains unclear whether choline that enters through P2X2 receptors is used to synthesize ACh because of the difficulties associated with measuring ACh concentrations in the cholinergic amacrine cells of the mouse retina.

Therefore, we herein investigated whether P2X2 receptor-expressing human embryonic kidney 293-derived cells, which express the simian virus 40 T antigen (HEK293T cells), synthesize ACh from choline entering through P2X2 receptors because human embryonic kidney 293-derived cells (HEK293 cells) synthesize ACh [28] (Fig. 3B). The results obtained revealed a significant increase in intracellular ACh concentrations ([ACh]i) in P2X2 receptor-expressing HEK293T cells when P2X2 receptor-mediated choline influx was activated. These results support choline transport through P2X2 receptors functioning as a second pathway for ACh synthesis in cholinergic neurons.

Materials and methods

Construction of an expression vector

A cDNA fragment of the P2X2 receptor was amplified from a mouse P2rx2/pdNA3 vector by PCR using the following primers (5'-CCGAGAATTCGCCGCCATGGCCGCTG-3' and 5'-CCGAGAATTCGCCGCCATGGCCGCTG-3'); cDNA was inserted into the EcoRI/Sall site of a pIRES2-AcGFP1-Nuc vector (TaKaRa Bio, Shiga, Japan). Since nuclear localization signals are fused to the GFP coding region, GFP is expressed in the nucleus.

Cell culture and transfection

HEK293T cells (RIKEN Bio-Resource Center, Tsukuba, Japan) were cultured in HEK medium consisting of Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, Taufkirchen, Germany) containing 10% FBS and hygromycin B (500 μg·mL⁻¹; Nacalai Tesque, Inc., Kyoto, Japan). HEK293T or ChAT-HEK293 cells were plated on 10-cm dishes (2 × 10⁶ cells per dish) maintained at 37 °C in a 5% CO₂/air atmosphere. HEK293T or ChAT-HEK293 cells were transfected with the pP2X2-IRES2-AcGFP1-Nuc vector (10 μg plasmid DNA per dish) using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions, and transfected cells were incubated for 2 days.

Immunocytochemistry

Immunocytochemistry was performed as described in our previous studies [27,30]. In brief, HEK293T or ChAT-HEK293 cells were fixed with 4% paraformaldehyde (w/v) in 0.1 M phosphate buffer (PB) for 30 min, permeabilized for 15 min in 0.1 M PB containing 0.3% Triton-X 100, and blocked with 0.1 M PB containing 1% Block Ace (Dainippon Seiyaku, Osaka, Japan) at room temperature for 60 min. Samples were reacted with a rabbit anti-P2X2 receptor (working dilution 1:500, Invitrogen) in 0.1 M PB containing 0.4% Block Ace at 4 °C for 24 h. Samples were then allowed to react with Alexa 594-conjugated goat anti-rabbit IgG (working dilution 1:500, Invitrogen) in 0.1 M PB at room temperature for 2 h and then counterstained with 4',6-diamidino-2-phenylindole (DAPI; working dilution 1:500, Nacalai Tesque, Inc., Kyoto, Japan). Fluorescent images were observed under a confocal microscope (FV1200; Olympus, Tokyo, Japan) at an excitation wavelength of 488 nm for GFP (bandpass 505–540 nm), 559 nm for Alexa 594 (bandpass 575–675 nm), and 405 nm for DAPI (bandpass 430–470 nm).

HPLC

HEK293T or ChAT-HEK293 cells were incubated in one of the choline-containing extracellular solutions shown in Table 1 with or without 30 μM ATP for 5 min. After washing with Dulbecco’s phosphate-buffered saline [free of Ca and Mg; DPBS (−)], cells were cultured in HEK or ChAT-HEK medium for 25 min to allow for ACh synthesis. After washing with DPBS (−) twice, collected cells were treated with 500 μL PCA solution containing 0.1 M perchloric acid, 0.1 mM EDTA, 100 μM isopropyl homocholine, and 0.1 mM eserine, a blocker of cholinesterase. Samples were centrifuged at 20,000 g at 0 °C

| Table 1. Composition of extracellular solutions (in mM). |
|---|---|---|---|---|---|---|---|
| NaCl | Choline Cl | KCl | MgCl₂ | CaCl₂ | HEPES | Glucose | Sucrose |
| Choline-rich | 0 | 135 | 5 | 1 | 2 | 5 | 10 | 0 |
| Choline-Na | 134.9 | 0.1 | 5 | 1 | 2 | 5 | 10 | 0 |
| Choline | 0 | 0.1 | 5 | 1 | 2 | 5 | 10 | 234 |
for 15 min. After adjusting pH to approximately 7.0 using 1 M KHCO₃, the supernatant was collected and filtered (Millipore Ultrafree MC 10,000 MW cutoff UFC3LG00; Millipore, Billerica, MA, USA) by centrifugation (14,000 g at room temperature for 20 min). The sample (10 μL) was injected into the HPLC system (HTEC-500; Eicom, Kyoto, Japan) equipped with a guard column (CH-Gel), separation column (AC-Gel), and immobilized enzyme column (AC-Enzyme Pack II) in series. The composition of the mobile phase was 50 mM KHCO₃, 300 mg L⁻¹ sodium 1-decanesulfonate, and 50 mg L⁻¹ EDTA. The flow rate of the mobile phase was 0.15 mL min⁻¹. Peak data were recorded and analyzed on a computer. In our system, the detection limit of the intracellular choline concentration was 0.1 nM. The choline concentration in each sample was estimated using the internal standard, isopropyl homocholine.

Western blot analysis

HEK293T or ChAT-HEK293 cells were washed twice with D-PBS (−) and directly lysed with 1 × SDS/PAGE sample buffer (62.5 mM Tris/HCl, 3 w/v% SDS, 7.5% glycerol, 0.005 w/v% bromophenol blue, and 50 mM dithiothreitol). All samples were run on e-PAGEL (ATTO, Tokyo, Japan) and then transferred onto a polyvinylidene fluoride membrane (Millipore). After blocking with 5% skim milk in Tris-buffered saline containing 0.1% Tween-20, membranes were processed through sequential incubations with goat anti-ChAT (working dilution 1:1000; Chemicon, Temecula, CA, USA) overnight and then with a horseradish peroxidase-conjugated anti-goat IgG antibody (working dilution 1:10,000, Jackson Laboratory, Bar Harbor, ME, USA) for 2 h. An internal standard, β-actin, was detected using anti-β-actin antibodies followed by a horseradish peroxidase-conjugated anti-mouse IgG antibody (working dilution 1:3000, Cell Signaling Technology, Danvers, MA, USA). Bound antibodies were visualized using a chemiluminescence imager (Amersham, Little Chalfont, UK), detected with Light-Capture (AE-6972; ATTO), and quantified using CS Analyzer (ver. 3.00 software; ATTO).

Statistical analysis

The significance of differences was calculated with Student’s t-test (Fig. 1C,D) or Steel-Dwass test (Fig. 2A–C). Details on the results of individual statistical analyses are described in the figure legends.

Results

The overexpression of the P2X₂ receptor does not affect ChAT expression levels

We examined whether the overexpression of the P2X₂ receptor in HEK293T or ChAT-HEK293 cells affected ChAT expression levels. Immunoreactivity for P2X₂ receptors was detected in GFP-positive cells in both cell lines, but not in untransfected cells (Fig. 1A,B). We then investigated whether untransfected HEK293T cells expressed ChAT similar to HEK293 cells [28]. The results obtained showed that ChAT was also expressed in HEK293T cells (Fig. 1C). Under untransfected conditions, ChAT expression levels were higher in ChAT-HEK293 cells than in HEK293T cells (Fig. 1C,D). The transfection of the pP2X₂-IRES2-AeGFP1-Nuc vector did not affect ChAT expression levels in either cell line (Fig. 1C,D).

Choline that enters cells through P2X₂ receptors is synthesized into ACh

In HEK293T cells expressing P2X₂ receptors, we previously reported that the application of ATP opened P2X₂ receptors, resulting in the extracellular influx of choline into the intracellular space [27]. In the present study, to clarify whether choline that enters through the P2X₂ receptor is used for ACh synthesis, we applied ATP to ChAT-HEK293 cells in choline-rich solution to maximize choline influx and the opportunity for ACh synthesis (Table 1). As a control, we incubated ChAT-HEK293 cells in culture medium (ChAT-HEK medium) for 5 min to assess basal [ACh], (Fig. 2A, Con). In P2X₂ receptor-expressing ChAT-HEK293 cells, the application of ATP significantly increased [ACh], (Fig. 2A, ATP (+)). A simple incubation of P2X₂ receptor-expressing ChAT-HEK293 cells in choline-rich solution did not significantly increase [ACh], (Fig. 2A, ATP (−)).

We then investigated whether choline entering through P2X₂ receptors induced significant increases in [ACh], under physiological conditions. We activated choline influx through P2X₂ receptors in a physiologically relevant concentration of choline and measured [ACh]. Since there are currently no available data on choline concentrations at the synaptic cleft, we estimated its concentration at this location. Based on the concentration of choline in plasma (5–10 μM) [11,23] and the maximum concentration of ACh at the synaptic cleft (>1000 μM) [31], we assumed that the concentration of choline at the synaptic cleft was 100 μM. In subsequent experiments, we used P2X₂ receptor-expressing HEK293T cells to efficiently separate the peak of ACh from that of choline in HPLC. We speculated that the synaptic cleft is filled with extracellular fluid; therefore, we investigated whether the influx of choline from Na-containing solution (Table 1, choline-Na solution) induced a significant increase in [ACh]. However, the application of ATP.
did not induce a significant increase in [ACh]i (Fig. 2B). We then replaced extracellular cations with equimolar sucrose and applied ATP to clarify the role of the P2X2 receptor in ACh synthesis through the influx of choline because sucrose does not compete with choline at the pores of P2X2 receptors (Table 1, choline solution). In choline solution, the application of ATP significantly increased [ACh]i (Fig. 2C).

**Discussion**

In cholinergic neurons, choline uptake through CHT1 is regarded as the only source for ACh synthesis (Fig. 3A). In the present study, we showed that choline entering through P2X2 receptors is also used for ACh synthesis. Our results support the hypothesis that P2X2 receptors function as a novel choline transport pathway for ACh synthesis (Fig. 3B).

The present results revealed an increase in [ACh]i in P2X2 receptor-expressing ChAT-HEK293 cells in choline-rich solution when cells were stimulated with ATP. Since intermediate- or low-affinity choline transporters are expressed and continuously function in various tissues [11,12], we speculated that the increase observed in [ACh]i was induced by the greater uptake of choline through these choline transporters. However, the significant increase observed in [ACh]i cannot be explained by choline uptake through these choline transporters because their activity remains stable in the presence and absence of ATP. However, the slight increase detected in [ACh]i after the incubation in choline-rich solution without ATP (Fig. 2A, ATP (−)) may be explained by choline uptake through these choline transporters.

We also demonstrated a significant increase in [ACh]i when the extracellular concentration of choline...
was 100 µM in choline solution. However, we did not detect a significant increase in [ACh]i when the extracellular concentration of choline was 100 µM in choline-Na solution even though an increase in [ACh]i appeared to occur (Fig. 2B). There are three possible explanations for this difference. It may be explained by competition between Na⁺ and choline⁺ at the cation channels of P2X2 receptors, similar to the anomalous mole fraction effects reported in Ca channels [32–36]. The permeability of choline⁺ to the P2X2 receptor is less than that of Na⁺ [27]. We observed a significant increase in [ACh]i in choline solution because choline⁺ freely permeates the cation channel of P2X2 receptors without competition from Na⁺ (Fig. 2A,C). Furthermore, the P2X2 receptor-coupled increase in [ACh]i synthesis may be masked by the endogenous synthesis of ACh in HEK293T cells. Previous studies reported the low endogenous expression of the P2X2 receptor in HEK293T cells [37]. If the extracellular level of ATP is high due to a leak from damaged cells [25,38] or release induced by a mechanical stimulation [39,40], ATP stimulates choline influx through the endogenous P2X2 receptor, thereby increasing the background level by competition between Na⁺ and choline⁺ at the cation channels of P2X2 receptors, similar to the anomalous mole fraction effects reported in Ca channels [32–36]. The permeability of choline⁺ to the P2X2 receptor is less than that of Na⁺ [27]. We observed a significant increase in [ACh]i in choline solution because choline⁺ freely permeates the cation channel of P2X2 receptors without competition from Na⁺ (Fig. 2A,C). Furthermore, the P2X2 receptor-coupled increase in [ACh]i synthesis may be masked by the endogenous synthesis of ACh in HEK293T cells. Previous studies reported the low endogenous expression of the P2X2 receptor in HEK293T cells [37]. If the extracellular level of ATP is high due to a leak from damaged cells [25,38] or release induced by a mechanical stimulation [39,40], ATP stimulates choline influx through the endogenous P2X2 receptor, thereby increasing the background level.
of [ACh]. In addition, although we estimated that the concentration of choline at the synaptic cleft was 100 μM, its actual concentration may be >100 μM because ACh concentrations at the synaptic cleft may increase to >1 mM [31]. If ACh is immediately degraded by cholinesterase under these conditions, the concentration of choline at the synaptic cleft may become higher than our estimate. There is currently no available data on the concentrations of various cations at the synaptic cleft or the distribution of P2X2 receptors at synapses; therefore, further studies are warranted.

We previously reported that choline entered the intracellular space through P2X2 receptors as ionic currents in the cholinergic neurons of the retina [27]. Choline transport by P2X2 receptors is only active when P2X2 receptors are stimulated, and the speed of choline transport by P2X2 receptors may be assessed based on the concentration gradient between intracellular and extracellular choline concentrations. These characteristics differ from conventional choline transport by CHT1 in cholinergic neurons. We also previously demonstrated that two types of retinal cholinergic neurons, ON- and OFF-type cholinergic amacrine cells, exhibited different patterns of immunoreactivity for P2X2 receptors and CHT1 [27,30]. CHT1 is expressed at a high level in ON-type cholinergic amacrine cells and at a low level in OFF-type cholinergic amacrine cells. On the other hand, P2X2 receptors are expressed at a low level in ON-type cholinergic amacrine cells and at a high level in OFF-type cholinergic amacrine cells. The present results strongly support the hypothesis that the main choline supply pathway for ACh synthesis differs between ON- and OFF-type cholinergic amacrine cells.

In the retina, ATP is released from Müller glial cells [41–43], pigment epithelial cells [44], dopaminergic neurons [45], and cholinergic amacrine cells [46]. Among these neurons, reciprocal synapses between cholinergic amacrine cells are the likely release site of ATP because cholinergic amacrine cells also release ACh. Therefore, cholinergic amacrine cells may activate P2X2 receptors to recycle choline for ACh synthesis. Similarly, cholinergic neurons in the central and peripheral nervous systems have been shown to release ATP [25]. In addition, some cholinergic neurons express P2X2 receptors [47–49]. Therefore, the P2X2 receptor-mediated ACh synthesis pathway may also be present in cholinergic neurons in other regions.

Based on our study series [27,30], we suggest that choline entering the intracellular space through P2X2 receptors in cholinergic neurons is used to synthesize ACh. In the brain, disorders of the cholinergic system are considered to cause Alzheimer’s disease, Parkinson’s disease, and schizophrenia [50–55]. Therefore, the present results may open new frontiers for the therapeutic manipulation of the cholinergic system in the brain.

**Acknowledgements**

The authors thank Dr. Ikuo Ogiwara, Dr. Atsushi Shimojohata, and Ms. Chiaki Suzuki for providing support during the experiments. This work was supported by a Grant-in-Aid for Scientific Research (C) from JSPS (KAKENHI No. 20K09836; to M. Kaneda), a Nippon Medical School Grant-in-Aid for Medical Research to M. Kaneda, a Grant-in-Aid for Young Scientists (B) from JSPS (KAKENHI No. 21K16910; to T. Maruyama), and a Grant-in-Aid for Scientific Research (C) from JSPS (KAKENHI No. 19K09939; to T. Ishii).

**Conflict of interest**

The authors declare no conflict of interest.

**Data accessibility**

The data are available from the corresponding author upon reasonable request.

**Author contributions**

MK, TM, TI, and YK designed the project. TM performed immunocytochemistry. TM prepared samples for the HPLC analysis. AM and YK performed the HPLC analysis. TM performed the western blot analysis. TM, TI, and MK wrote the manuscript. All authors have read and approved the final manuscript.

**References**

1 Collier B, Poon P, Salehmoghaddam S. The formation of choline and of acetylcholine by brain in vitro. *J Neurochem*.1972;19:51–60.
2 Haubrich DR, Chippendale TJ. Regulation of acetylcholine synthesis in nervous tissue. *Life Sci*.1977;20:1465–78.
3 Hebb C. Biosynthesis of acetylcholine in nervous tissue. *Physiol Rev.*1972;52:918–57.
4 Tucek S. The synthesis of acetylcholine: twenty years of progress. *Prog Brain Res.*1990;84:467–77.
5 Brown DA. Acetylcholine and cholinergic receptors. *Brain Neurosci Adv*.2019;3:2398212818820506.
6 Feldberg W. Transmission in the central nervous system and sensory transmission. *Pharmacol Rev.*1954;6:85–93.
Novel pathway for acetylcholine synthesis

T. Maruyama et al.

7 Krnjevic K. Chemical nature of synaptic transmission in vertebrates. Physiol Rev. 1974;54:418–540.
8 Phillis JW. Acetylcholine release from the central nervous system: a 50-year retrospective. Crit Rev Neurobiol. 2005;17:161–217.
9 Shute CC, Lewis PR. Cholinergic pathways. Pharmacol Ther B. 1975;1:79–87.
10 Woolf NJ. A structural basis for memory storage in mammals. Prog Neurobiol. 1998;55:59–77.
11 Lockman PR, Allen DD. The transport of choline. Drug Dev Ind Pharm. 2002;28:749–71.
12 Inazu M. Functional expression of choline transporters in the blood-brain barrier. Nutrients. 2019;11.
13 Ferguson SM, Savchenko V, Apparsundaram S, Zwick M, Wright J, Heilman CJ, et al. Vesicular localization and activity-dependent trafficking of presynaptic choline transporters. J Neurosci. 2003;23:9697–709.
14 Haga T. Molecular properties of the high-affinity choline transporter CHT1. J Biochem. 2014;154:181–94.
15 Misawa H, Nakata K, Matsuura J, Nagao M, Okuda T, Haga T. Distribution of the high-affinity choline transporter in the central nervous system of the rat. Neuroscience. 2001;105:87–98.
16 Ribeiro FM, Black SA, Prado V, Rylett RJ, Ferguson SS, Prado MA. The "ins" and "outs" of the high-affinity choline transporter CHT1. J Neurochem. 2006;97:1–12.
17 Bazalakova MH, Wright J, Schneble EJ, McDonald MP, Heilman CJ, Levey AI, et al. Deficits in acetylcholine homeostasis, receptors and behaviors in choline transporter heterozygous mice. Genes Brain Behav. 2007;6:411–24.
18 Wu CF, Bertorelli R, Sacconi M, Pepeu G, Consolo S. Decrease of brain acetylcholine release in aging freely-moving rats detected by microdialysis. Neurobiol Aging. 1988;9:357–61.
19 Massey SC, Neal MJ. Release of [3H]-acetylcholine from the isolated retina of the rat by potassium depolarization: dependence on high affinity choline uptake. Br J Pharmacol. 1979;65:271–6.
20 Fujii T, Masai M, Misawa H, Okuda T, Takada-Takatori Y, Moriwaki Y, et al. Acetylcholine synthesis and release in NIH3T3 cells coexpressing the high-affinity choline transporter and choline acetyltransferase. J Neurosci Res. 2009;87:3024–32.
21 Ojiakor OA, Rylett RJ. Modulation of sodium-coupled choline transporter CHT function in health and disease. Neurochem Int. 2020;140:104810.
22 Michel V, Yuan Z, Ramsubir S, Bakovic M. Choline transport for phospholipid synthesis. Exp Biol Med (Maywood). 2006;231:490–504.
23 Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition. Nat Rev Neurosci. 2005;6:48–56.
24 Massey SC, Redburn DA. The cholinergic amacrine cells of rabbit retina receive on and off input: an analysis of [3H]-ACh release using 2-amino-4-phosphonobutyric acid (APB) and chloride free medium. Vision Res. 1983;23:1615–20.
25 Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev. 2007;87:659–797.
26 North RA. Molecular physiology of P2X receptors. Physiol Rev. 2002;82:1013–67.
27 Ishii T, Homma K, Mano A, Akagi T, Shigematsu Y, Shimoda Y, et al. Novel channel-mediated choline transport in cholinergic neurons of the mouse retina. J Neurophysiol. 2017;118:1952–61.
28 Takatori Y, Moriwaki Y, et al. Acetylcholine synthesis and release in NIH3T3 cells coexpressing the high-affinity choline transporter and choline acetyltransferase. J Neurochem Int. 2020;82:48–56.
29 Shimoda Y, et al. Novel channel-mediated choline transport in cholinergic neurons of the mouse retina. J Neurophysiol. 2017;118:1952–61.
30 Oikawa S, Iketani M, Takatori Y, Akiyama T, Yamazaki Y, Nakanishi S, et al. OFF-cholinergic-pathway-selective localization of P2X2 purinoceptors in the mouse retina. J Comp Neurol. 2009;516:5111–25.
31 Gibb AJ. Choline and acetylcholine: what a difference an acetate makes! J Physiol. 2017;598:1021–2.
32 Almers W, McCleskey EW. Non-selective conductance in calcium channels of frog muscle: calcium selectivity in a single-file pore. J Physiol. 1984;353:585–608.
33 Byerly L, Chase PB, Stimers JR. Permeation and interaction of divalent cations in calcium channels of snail neurons. J Gen Physiol. 1985;85:491–518.
34 Campbell DL, Giles WR, Shibata EF. Ion transfer characteristics of the calcium current in bullfrog atrial myocytes. J Physiol. 1988;403:239–66.
35 Hess P, Lansman JB, Tsien RW. Different modes of Ca channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists. Nature. 1984;311:538–44.
36 McDonald TF, Cavaliere A, Trautwein W, Pelzer D. Voltage-dependent properties of macroscopic and elementary calcium channel currents in guinea pig ventricular myocytes. Pflugers Arch. 1986;406:437–48.
37 Vulchanova L, Arvidsson U, Riedl M, Wang J, Buell G, Surprenant A, et al. Differential distribution of two ATP-gated channels (P2X receptors) determined by immunocytochemistry. Proc Natl Acad Sci USA. 1996;93:8063–7.
38 Cook SP, McCleskey EW. Cell damage excites nociceptors through release of cytosolic ATP. Pain. 2002;95:41–7.
39 Burnstock G, Knight GE. Cell culture: complications due to mechanical release of ATP and activation of purinoceptors. Cell Tissue Res. 2017;370:1–11.
40 Mikolajewicz N, Zimmermann EA, Willie BM, Komarova SV. Mechanically stimulated ATP release from murine bone cells is regulated by a balance of injury and repair. *Elife*. 2018;7:e37812.
41 Loiola EC, Ventura AL. Release of ATP from avian Muller glia cells in culture. *Neurochem Int*. 2011;58:414–22.
42 Newman EA. Glial cell inhibition of neurons by release of ATP. *J Neurosci*. 2003;23:1659–66.
43 Newman EA. Glial modulation of synaptic transmission in the retina. *Glia*. 2004;47:268–74.
44 Reigada D, Mitchell CH. Release of ATP from retinal pigment epithelial cells involves both CFTR and vesicular transport. *Am J Physiol Cell Physiol*. 2005;288:C132–40.
45 Ho T, Jobling AI, Greferath U, Chuang T, Ramesh A, Fletcher EL, et al. Vesicular expression and release of ATP from dopaminergic neurons of the mouse retina and midbrain. *Front Cell Neurosci*. 2015;9:389.
46 Santos PF, Caramelo OL, Carvalho AP, Duarte CB. Characterization of ATP release from cultures enriched in cholinergic amacrine-like neurons. *J Neurobiol*. 1999;41:340–8.
47 Ma B, Ruan HZ, Burnstock G, Dunn PM. Differential expression of P2X receptors on neurons from different parasympathetic ganglia. *Neuropharmacology*. 2005;48:766–77.
48 Misawa R, Girotti PA, Mizuno MS, Liberti EA, Furness JB, Castelucci P. Effects of protein deprivation and re-feeding on P2X2 receptors in enteric neurons. *World J Gastroenterol*. 2010;16:3651–63.
49 Scheibler P, Pesic M, Franke H, Reinhardt R, Wirkner K, Illes P, et al. P2X2 and P2Y1 immunofluorescence in rat neostriatal medium-spiny projection neurones and cholinergic interneurons is not linked to respective purinergic receptor function. *Br J Pharmacol*. 2004;143:119–31.
50 Acharya S, Kim KM. Roles of the functional interaction between brain cholinergic and dopaminergic systems in the pathogenesis and treatment of schizophrenia and Parkinson’s disease. *Int J Mol Sci*. 2021;22:4299.
51 Ahmed NY, Knowles R, Dehorter N. New insights into cholinergic neuron diversity. *Front Mol Neurosci*. 2019;12:204.
52 Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer’s disease: targeting the cholinergic system. *Curr Neuropharmacol*. 2016;14:101–15.
53 Liu C. Targeting the cholinergic system in Parkinson’s disease. *Acta Pharmacol Sin*. 2020;41:453–63.
54 Lombardo S, Maskos U. Role of the nicotinic acetylcholine receptor in Alzheimer’s disease pathology and treatment. *Neuropharmacology*. 2015;96:255–62.
55 Schliebs R, Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease. *J Neural Transm (Vienna)*. 2006;113:1625–44.